Myriad Revenues Grow 9 Percent in Q1 | GenomeWeb

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday that its fiscal first quarter revenues grew by 9 percent from the year-ago quarter, beating analysts' consensus top-line estimate. 

The molecular diagnostics firm brought in total revenues of $183.5 million for the three months ended Sept. 30, compared to $168.8 million in Q1 2015, and above the consensus Wall Street estimate of $177.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.